Outlook Therapeutics(OTLK)
8.95 -0.27 -2.9284%
| 今开：9.18 | 昨收：9.22 |
| 最高：9.25 | 最低：8.83 |
| 涨停价：0.0 | 跌停价：0.0 |
| 总市值：2.09480451E8 |
Outlook Therapeutics的热门讨论
招股说明书
Outlook Therapeutics(OTLK)05-07 04:15
$Outlook Therapeutics(OTLK)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001104659-24-057439 Act: 33 Size: 125 KB 网页链接查看全文
生效批准
Outlook Therapeutics(OTLK)05-07 18:05
$Outlook Therapeutics(OTLK)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001396 Act: 33 Size: 1 KB 网页链接查看全文
当期报告
Outlook Therapeutics(OTLK)05-29 04:45
$Outlook Therapeutics(OTLK)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-065609 Act: 34 Size: 195 KB 网页链接查看全文
增发股票注册声明
Outlook Therapeutics(OTLK)04-27 04:25
$Outlook Therapeutics(OTLK)$ S-3 Registration statement under Securities Act of 1933 Accession Number: 0001104659-24-052965 Act: 33 Size: 229 KB 网页链接查看全文
当期报告
Outlook Therapeutics(OTLK)07-08 20:45
$Outlook Therapeutics(OTLK)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-078207 Act: 34 Size: 195 KB 网页链接查看全文
季度财报
Outlook Therapeutics(OTLK)05-16 05:25
$Outlook Therapeutics(OTLK)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-008318 Act: 34 Size: 7 MB 网页链接查看全文
当期报告
Outlook Therapeutics(OTLK)05-01 18:15
$Outlook Therapeutics(OTLK)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-055141 Act: 34 Size: 240 KB 网页链接查看全文
当期报告
Outlook Therapeutics(OTLK)05-14 04:15
$Outlook Therapeutics(OTLK)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-24-060517 Act: 34 Size: 221 KB 网页链接查看全文
当期报告
Outlook Therapeutics(OTLK)05-16 05:25
$Outlook Therapeutics(OTLK)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-062054 Act: 34 Size: 310 KB 网页链接查看全文
股东委托书协议
Outlook Therapeutics(OTLK)06-26 19:35
$Outlook Therapeutics(OTLK)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-24-074966 Act: 34 Size: 1 MB 网页链接查看全文
Outlook Therapeutics的最新讨论
网络异常请稍后再试2020-08-27 06:28
$Outlook Therapeutics(OTLK)$ Outlook Therapeutics (NASDAQ:OTLK) slumps 37% premarket on robust volume in reaction to topline results from a Phase 3 clinical trial, NORSE-1, evaluating Lytenava (bevacizumab-vikg) (formerly ONS-5010), an ophthalmic formulation of Roche's (O...查看全文
![[加油]](http://js.xueqiu.com/ugc/images/face/emoji_05_struggle.png?v=1 "[加油]"){kind=small}
![[俏皮]](http://js.xueqiu.com/ugc/images/face/emoji_04_cool.png?v=1 "[俏皮]"){kind=small}
Outlook Therapeutics的公告
当期报告
$Outlook Therapeutics(OTLK)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-078207 Act: 34 Size: 195 KB 网页链接
股东委托书协议
$Outlook Therapeutics(OTLK)$ DEF 14A Other definitive proxy statements Accession Number: 0001104659-24-074966 Act: 34 Size: 1 MB 网页链接
其他
$Outlook Therapeutics(OTLK)$ PRE 14A Other preliminary proxy statements Accession Number: 0001104659-24-071756 Act: 34 Size: 1 MB 网页链接
当期报告
$Outlook Therapeutics(OTLK)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-065609 Act: 34 Size: 195 KB 网页链接
季度财报
$Outlook Therapeutics(OTLK)$ 10-Q Quarterly report [Sections 13 or 15(d)] Accession Number: 0001558370-24-008318 Act: 34 Size: 7 MB 网页链接
当期报告
$Outlook Therapeutics(OTLK)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001104659-24-062054 Act: 34 Size: 310 KB 网页链接
当期报告
$Outlook Therapeutics(OTLK)$ 8-K Current report, items 8.01 and 9.01 Accession Number: 0001104659-24-060517 Act: 34 Size: 221 KB 网页链接
生效批准
$Outlook Therapeutics(OTLK)$ EFFECT Notice of Effectiveness Accession Number: 9999999995-24-001396 Act: 33 Size: 1 KB 网页链接
招股说明书
$Outlook Therapeutics(OTLK)$ 424B3 Prospectus [Rule 424(b)(3)] Accession Number: 0001104659-24-057439 Act: 33 Size: 125 KB 网页链接
当期报告
$Outlook Therapeutics(OTLK)$ 8-K Current report, item 8.01 Accession Number: 0001104659-24-055141 Act: 34 Size: 240 KB 网页链接